medRxiv
September 10, 2024
Benjamin Brake, Lillian Wieder, Natasha Hughes et al.
2 citations
preprint
Dissociative states—disruptions in awareness and perception—occur across many psychiatric disorders and can be experimentally induced. This meta-analysis of 123 studies (6,692 individuals) measured state dissociation using a standard scale. At baseline, the largest effects were in dissociative and complex subtypes of post-traumatic stress disorder (PTSD-DC). In controlled experiments, mirror-gazing and several drugs (especially ketamine and cannabis) produced dissociation levels as high as or higher than baseline PTSD-DC. Effect sizes varied widely but were not consistently linked to study methods. The findings confirm that dissociation can be reliably modeled in the lab, with implications for measuring side effects and predicting outcomes in drug-based treatments.
medRxiv
August 26, 2024
Tereza Klučková, Filip Tylš, Vojtěch Viktorin et al.
2 citations
preprint
In healthy volunteers, two doses of psilocybin (0.26 mg/kg) given at least 56 days apart produced moderate acute psychedelic effects that were mostly pleasant or fluctuating, with only one unpleasant experience. All sessions ended in a positive or neutral state. Psilocybin led to sustained positive effects across all domains of the Persisting Effects Questionnaire, with negligible negative effects. Contrary to expectations, dread of ego dissolution was not linked to negative long-term outcomes. Peak experiences culminating in positive mood were associated with positive lasting effects, while the type of experience (pleasant or mixed) did not correlate with the intensity or direction of the lasting effect. Results were independent of previous psychedelic experience, sex, or study setting.
medRxiv
January 17, 2023
Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al.
2 citations
preprint
Ketamine-Assisted Psychotherapy (KAP) produced large and sustained reductions in depression, anxiety, and PTSD symptoms for up to six months after treatment. In a retrospective trial of 1806 adults with treatment-resistant depression, anxiety, or PTSD, effect sizes at three months ranged from 0.75 to 0.86 and were maintained at six months (0.61 to 0.73). Between 39% and 41% of patients showed case reductions at three months, and 29% to 37% at six months. A minimal clinically important difference was reported by 50% to 75% at three months and 48% to 70% at six months. The treatment involved 4 to 6 guided ketamine sessions with psychotherapy.
medRxiv
June 16, 2021
Tammi R. A. Kral, Kaley Davis, Cole Korponay et al.
2 citations
preprint
A large, rigorously controlled study combining data from two three-arm randomized controlled trials found no evidence that an eight-week Mindfulness-Based Stress Reduction (MBSR) course produces changes in brain structure. Meditation-naive participants (218 total) were randomly assigned to a waitlist, an 8-week MBSR program, or a validated active control group. Structural MRI scans taken before and after the intervention showed no significant differences in gray matter volume, gray matter density, or cortical thickness between MBSR and either control group, at either the whole-brain level or in brain regions previously linked to MBSR. These results fail to replicate earlier, widely cited claims of MBSR-induced neuroplasticity.
medRxiv
January 16, 2026
Kristian Larsen, Patrick M Fisher, Drummond E. Mcculloch et al.
1 citation
Classical psychedelics such as LSD, psilocybin, and mescaline produce distinct changes in brain complexity and entropy that are not seen with stimulants like MDMA or d-Amphetamine. Using resting-state fMRI data from three placebo-controlled crossover trials with 79 participants across 255 sessions, the study found that psychedelics specifically increased meta-state complexity, short-timescale multiscale entropy, and dynamic conditional correlation entropy. Both drug classes increased Lempel-Ziv and spatial complexity and decreased absolute modularity, but only psychedelics showed these unique complexity and entropy increases. These findings suggest that psychedelic-specific brain signal changes may help distinguish the acute psychedelic state from other psychoactive drug effects and could be relevant to understanding their therapeutic potential.
medRxiv
December 23, 2025
Chiranth Bhagavan, O. Carter, Glenn Nielsen et al.
1 citation
Movement tasks such as walking, reaching, and dexterity tests were feasible for healthy volunteers who took psilocybin doses up to 15 mg. At 20 mg, impairments appeared in tasks that combined movement with cognitive demands, such as the Box and Block Test and Digit Symbol Substitution Test. Nausea (62% of participants) and headache (54%) were the most common adverse events; no serious adverse events occurred. Participants and physiotherapists guessed the dose correctly only about half the time, indicating adequate blinding. These results suggest that psilocybin-assisted physical rehabilitation may be safe and feasible for future trials in people with movement disorders.
medRxiv
September 25, 2025
B Gowthami, Ishita Mehta, Sneha Baiju et al.
1 citation
preprint
Adding esketamine nasal spray to an oral antidepressant improves treatment response, remission, and daily functioning in people with treatment-resistant depression, but it also raises the risk of dissociation and hypertension. A systematic review pooled data from 17 randomized controlled trials involving 10,073 patients. Esketamine plus an antidepressant roughly doubled the odds of achieving a 50% reduction in depressive symptoms and nearly tripled the odds of remission compared to placebo plus an antidepressant. Functional disability scores also improved more with esketamine. However, continuous measures of depression severity showed no statistically significant difference between groups. Safety analysis found that dissociation was about twice as likely and hypertension about 40% more likely with esketamine, while sedation and nausea risks were not significantly elevated.
medRxiv
August 27, 2025
Md. Shahidul Islam, Md Sakib Ibne Salam, Md Nahid Hasan
1 citation
preprint
Unsupervised automatic text summarization was applied to 1,200 user experience reports of LSD, psilocybin, and DMT. Three extractive methods—LexRank, LSA with HDBSCAN clustering, and SBERT with Maximal Marginal Relevance—were compared using a custom scoring function that measures semantic coverage, narrative coherence, and experiential preservation. LexRank achieved the best overall balance, while SBERT excelled in content coverage and experiential depth but lacked coherence. Trade-offs between content richness and narrative fluency varied across substances due to differences in narrative structure. The study suggests that extractive summarization can help make subjective psychedelic reports more clinically useful, though future work should explore abstractive methods and expert adjudication.
medRxiv
June 25, 2025
Devon Stoliker, Fosco Bernasconi, Olaf Blanke et al.
1 citation
preprint
Psilocybin reduces effective connectivity between the right and left anterior insula and between the right anterior insula and right temporoparietal junction in people who report intense out-of-body experiences. These changes parallel disruptions in TPJ–insula circuits observed in clinical and experimental OBEs, particularly in the right hemisphere. The findings highlight how psilocybin-induced disembodiment corresponds to altered causal neural dynamics underlying bodily self-consciousness.
medRxiv
May 27, 2025
Nathan J Wellington, Ana Paula Bouças, Paul Schwenn et al.
1 citation
preprint
People with post-traumatic stress disorder who had a sustained clinical response to oral ketamine showed distinct baseline differences in DNA methylation and gene expression across 112 genes compared with non-responders. Key biomarkers included DENND5B, ZFY, PDGFRA, CPT1A, AHRR, and others involved in metabolism, cell signaling, neuronal development, immune response, and synaptic plasticity. Non-responders had persistent dysregulation in these pathways, suggesting biological barriers to treatment. Clinically, sustained responders had more severe PTSD at baseline and responded at lower ketamine doses. The findings point toward molecular profiling that could help personalize ketamine therapy for PTSD.
medRxiv
February 7, 2025
Jakub Vohryzek, Anne Maj van der Velden, Willem Kuyken et al.
1 citation
preprint
Mindfulness-based cognitive therapy (MBCT) alters brain network dynamics during depressive rumination in people with recurrent depression. In a randomized trial, 27 patients received MBCT plus treatment as usual, while 21 received treatment as usual alone. Using fMRI, researchers analyzed brain substates during an induced rumination state before and after treatment. MBCT changed the probability of a specific 'Salience-somatomotor' brain substate occurring during rumination, compared to the control group. These dynamic network changes were linked to reduced depressive symptoms after treatment and at three months follow-up, suggesting a candidate brain mechanism for how mindfulness training improves clinical outcomes.
medRxiv
November 20, 2024
Jan Ramaekers, Johannes T. Reckweg, Natasha L. Mason et al.
1 citation
preprint
In the first human study of 3-methylmethcathinone (3-MMC), a synthetic cathinone designer drug, 14 participants received escalating doses of 25, 50, and 100 mg in a placebo-controlled crossover trial. The drug caused dose-dependent increases in heart rate and blood pressure that were not clinically significant, along with subjective feelings of being high. 3-MMC also enhanced performance across several neurocognitive domains, including processing speed, cognitive flexibility, psychomotor function, attention, and memory, without affecting impulse control. Participants reported mild dissociative and psychedelic effects, decreased appetite, and transient increases in drug liking and wanting. The cardiovascular and psychostimulant profile resembles amphetamine-related compounds. Low to moderate doses were well tolerated and safe, with potential health risks likely only at high or excessive doses.
medRxiv
November 1, 2024
Dila Suay, Helena D. Aicher, Micheal Kometer et al.
1 citation
preprint
A psychedelic formulation combining DMT and harmine, inspired by ayahuasca, blurs the brain's distinction between self and other faces. In a double-blind, placebo-controlled experiment with 31 healthy men, the DMT/harmine combination increased early visual brain responses (P1 amplitude) and disrupted the structural encoding of faces (reduced N170 amplitude) for all face types. It also specifically reduced the brain's later response (P300) to one's own face, making the neural reaction to self-faces more similar to that for familiar or unknown faces. Harmine alone did not produce these effects. The findings suggest psychedelics may reduce attentional focus on self-referential information, potentially explaining feelings of unity and enhanced empathy.
medRxiv
July 12, 2024
Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto et al.
1 citation
preprint
Psilocybin mushrooms pose a very low risk of adverse events requiring medical attention in Brazil. Analyzing over 112,000 drug-related reports from 2007 to 2022, only 13 involved psilocybin mushrooms, with no deaths and a hospitalization rate of 46.2% (6 cases), representing just 0.02% of all hospitalizations. By contrast, alcohol accounted for 49.2% of toxic agent reports and 45.0% of hospitalizations, while cocaine was linked to 33.3% of deaths. The findings suggest current drug policy, which classifies psilocybin as high abuse potential, may not reflect its actual public health risk, supporting evidence-based regulatory discussions for clinical and ceremonial use.
medRxiv
February 15, 2023
Victoria di Virgilio, Amir Minerbi, Jenna Fletcher et al.
1 citation
preprint
Veterans who used psychedelic medicines for non-recreational therapeutic purposes reported improvements in medical and mental health conditions, social interaction, spirituality, and overall function. Analysis of 93 comments from 65 civilian or military veterans identified themes including mysticism and spirituality, functional improvement and self-awareness, social connection and cultural impact, and impact on medical and mental health conditions, as well as neutral impressions and difficult experiences. The findings suggest that psychedelic use is associated with multidimensional wellness improvements beyond the absence of disease, reflecting dynamic interactions with personal, psychophysiological, and socio-environmental factors.
medRxiv
January 21, 2022
Latifah Kamal, Major Pauline Godsell, Bryce P. Mulligan et al.
1 citation
preprint
A dashboard system called SENSOR (Standardized Data Entry and Dashboards for Review of Scientific Studies) was developed to improve how scientific literature reviews communicate data. The system was tested on an existing review about clinical applications of psychedelics for mental health issues. Two team members entered 46 study entries, including 3 articles published after the original review to show ease of updating. The dashboard displayed the data in various visual representations. Using a dynamic, graphical display for review studies proved feasible and offers advantages such as standardizing reporting, centralizing datasets, streamlining submissions, improving collaboration, measuring author contributions, and enhancing patient involvement. Limitations include heterogeneity in study design, dosing, indications, and outcome measures.
medRxiv
July 17, 2026
Amandine Fernandez, Alexandre Foncelle, Hélène Meunier et al.
Auto-Induced Cognitive Trance (AICT), a non-ordinary state of consciousness entered by will alone after learning a standardized procedure, is associated with greater well-being. Among 607 survey respondents (436 AICT-trained, 171 yet-to-be trained), practitioners reported higher self-esteem and overall connectedness—to self, others, and the world—than non-practitioners. Longer AICT practice was linked to further benefits: lower trait anxiety, higher positive affect, and stronger connectedness. The findings suggest AICT may improve well-being shortly after training, with continued practice yielding added gains in anxiety reduction and positive mood.
medRxiv
July 10, 2026
Lada Kohoutová, Jevita Potheegadoo, Léa F Duong Phan Thanh et al.
Hallucinations in Parkinson's disease, from minor to structured, are linked to changes in brain connectivity and cognitive decline. Non-demented patients with minor or structured hallucinations share a common pattern of resting-state functional connectivity that is absent in patients without hallucinations. This pattern involves connections between subcortical areas and visual, attention, and default mode networks, as well as within-cerebellar and within-subcortical connectivity. The pattern is equally expressed in both hallucination groups and is associated with impairments in attention and executive function, as well as increased sensitivity to an experimental procedure that induces presence hallucinations. The findings suggest that altered subcortical-cortical connectivity underlies hallucinations even in their early, minor forms.
medRxiv
July 8, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Yonatan Sanz Perl et al.
In people with major depressive disorder, mindfulness-based cognitive therapy (MBCT) plus treatment as usual, compared to treatment as usual alone, alters whole-brain dynamics in ways that may reduce rumination. Using a novel method called complex harmonics decomposition on fMRI data from 80 patients, the study identified low-dimensional spatiotemporal manifolds that capture both local and long-range brain interactions. After MBCT, during rumination, brain regions involved in bodily and interoceptive processing became more consistently integrated across these manifolds. The latent configurations shifted with clinical and behavioral improvements, and the brain showed greater flexibility within the reduced space. These changes may reflect reduced 'stickiness' of ruminative thinking patterns following mindfulness training.
medRxiv
July 4, 2026
Marco Zierhut, Max Alt, Inge Maria Hahne et al.
Combining intranasal oxytocin with mindfulness-based group therapy may improve negative symptoms in schizophrenia spectrum disorders. In a pilot study, 47 participants received either oxytocin or placebo before four therapy sessions. Only the oxytocin group showed significant reductions in negative symptoms from baseline to post-intervention and at a 4-week follow-up, with small between-group effects favoring oxytocin at follow-up. No serious adverse events occurred. The findings support further large-scale trials.
medRxiv
June 23, 2026
Paulina Clara Dagnino, Anne Maj van der Velden, Henricus G. Ruhé et al.
In people with major depressive disorder, mindfulness-based cognitive therapy (MBCT) plus treatment as usual, compared to treatment as usual alone, increased the hierarchical organization of brain activity during rumination but not at rest. Greater hierarchy—meaning more directional information flow and less recurrent looping—was linked to improvements in clinical and behavioral outcomes. This shift away from self-reinforcing negative mental loops toward more differentiated cognitive and bodily cycles may help explain how MBCT interrupts ruminative thought patterns. Hierarchical brain dynamics could serve as a treatment-sensitive marker and potential mechanism of therapeutic change in MBCT for depression.
medRxiv
June 22, 2026
Roi Basch, Maya Cohen, Leehe Peled‐avron
Serotonin-boosting treatments, such as SSRIs and psychedelics, consistently reduce repetitive negative thoughts like rumination, worry, and obsessions, but do not reliably improve performance on lab tests of cognitive flexibility. A meta-analysis of 2,030 participants across 45 effect sizes found that acute tryptophan depletion did not impair cognitive flexibility, and serotonin elevation did not enhance it. However, serotonin elevation produced a medium-to-large reduction in pathological perseverative thinking. The effect was stronger in samples with more female participants, and psilocybin showed a marginally larger reduction than SSRIs. The findings suggest serotonin's role in emotional and cognitive rigidity is distinct from its effects on objective executive function.
medRxiv
June 1, 2026
Erica J. Li, Basmah Mosharraf, Hiba Ali et al.
In a survey of 295 adults with musculoskeletal pain attending a hospital orthopaedic clinic, most perceived psilocybin as moderately to highly effective for pain (76%) and expressed moderate-to-high willingness to try microdoses (58%) or macrodoses (53%) of psilocybin for pain. Prior non-therapeutic psychedelic use was the strongest predictor of willingness to try a macrodose (B=3.16) or microdose (B=2.82), while pain severity had a small but significant effect. Only 3% had discussed psychedelics with a healthcare provider, and health risks were the primary concern (33%). The findings suggest neutral-to-positive perceptions, with gaps in patient knowledge and health concerns as key barriers to address in future trials.
medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
Under Oregon's regulated psilocybin program, adults who consumed an average of 27.8 mg of psilocybin showed significant improvements in depression, anxiety, and well-being 30 days after a session, including those concurrently using psychiatric medication. Of 88 participants (median age 43, 52% male, 64.8% with prior psychedelic experience), two reported symptoms of hallucinogen persisting perception disorder one day after the session, but none at 30 days. The findings suggest that legal psilocybin services can produce clinically meaningful mental health benefits.
medRxiv
December 1, 2025
Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al.
preprint
In a real-world clinical setting, a single dose of LSD (100 µg) or psilocybin (25 mg) combined with psychotherapy significantly reduced depression and anxiety symptoms in 115 adults with treatment-resistant disorders. Symptoms were measured one to three months after treatment, with no serious adverse events. Patients also showed reduced rumination, self-blame, and catastrophizing, along with increased positive refocusing and reappraisal. Both substances produced comparable clinical benefits despite different subjective effect profiles. The findings suggest that psychedelic-assisted psychotherapy is feasible and effective in routine specialized care.